9.46
+0.515(+5.76%)
Currency In USD
Address
Chemin des Mines, 9
Geneva, 1202
Switzerland
Phone
41 22 884 1555
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
February 12, 2020
| Name | Title | Pay | Year Born |
| Mr. Timothy Mark Dyer | Co-Founder, Chief Executive Officer & Director | 0 | 1968 |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director | 33,223 | 1957 |
| Mr. Lénaic Teyssédou | Head of Finance | 0 | 1986 |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science | 0 | 1967 |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.